Legend Biotech Corporation (LEGN) NASDAQ

32.06

-0.23(-0.71%)

Updated at October 03 04:00PM

Currency In USD

Legend Biotech Corporation

Address

2101 Cottontail Lane

Somerset, NJ 08873

United States of America

Phone

732 317 5050

Sector

Healthcare

Industry

Biotechnology

Employees

2600

First IPO Date

June 05, 2020

Key Executives

NameTitlePayYear Born
Dr. Ying Huang Ph.D.Chief Executive Officer & Director01973
Mr. Tim RobertsGlobal Compliance Officer0N/A
Mr. Birk VanderweeenSenior Vice President of Global Manufacturing & Supply0N/A
Ms. Elaine QianVice President & Global Head of Human Resources0N/A
Ms. Caroline LeCates PaulAssociate Director of Investor Relations0N/A
Dr. Mythili Koneru M.D., Ph.D.Chief Medical Officer01979
Mr. Shu WuSenior Vice President of Global Operations & GM of Legend China0N/A
Ms. Jessie Yeung M.B.A.Interim Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer01985
Dr. Guowei Fang Ph.D.President of Research & Development0N/A
Mr. James Pepin J.D.General Counsel0N/A

Description

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.